×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📊
Dashboards
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Dashboards
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
←
Home
/
Wiki
/
Therapeutic: Advanced Computational Neuroscience and AI-Driven Drug Disco
therapeutic
2,232 words
KG: ent-dise-bfd8f32d
Contents
Advanced Computational Neuroscience and AI-Driven Drug Discovery for CBS/PSP
💊
Therapeutic Info
Name
ent-dise-bfd8f32d
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (23)
Purinergic Signaling Polarization Control
Score: 0.71
Mechanosensitive Ion Channel Reprogramming
Score: 0.70
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.78
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
APOE-TREM2 Interaction Modulation
Score: 0.74
APOE Isoform Conversion Therapy
Score: 0.72
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.70
Extracellular Matrix Stiffness Modulation
Score: 0.69
pg 1/2
Next →
Related Analyses (16)
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · completed
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Show 11 more
Related Experiments (23)
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · completed · Score: 0.90
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
Multi-omics analysis of myricanol effects on gene expression
exploratory · proposed · Score: 0.88
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.45
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.45
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Experiment: Multi-Ethnic PD GWAS
clinical · proposed · Score: 0.40
Show 18 more
See Also (15)
Shared Mechanisms Between Alzheimer and Parkinson Disea
mechanism · Pages share 4 hypotheses
Convergent Pathways in Neurodegeneration
mechanism · Pages share 4 hypotheses
Synaptic Therapy Alzheimer's Research Trial (START): A
clinical · Pages share 4 hypotheses
ABCA7 Lipid Transport and Microglial Phagocytosis AD Ca
mechanism · Pages share 4 hypotheses
APOE4 and Alzheimer's Disease Risk
mechanism · Pages share 4 hypotheses
C9orf72 Repeat Expansions in CBS and PSP
mechanism · Pages share 4 hypotheses
Speech and Cognitive Biomarkers for Alzheimer's Disease
biomarker · Pages share 4 hypotheses
VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers
biomarker · Pages share 4 hypotheses
A Phase 3, Randomised, Double-blinded, Placebo-controll
clinical · Pages share 4 hypotheses
Rotigotine and Rivastigmine Combination Therapy for Alz
clinical · Pages share 4 hypotheses
Antibody Therapy in Neurodegeneration
mechanism · Pages share 4 hypotheses
NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease
biomarker · Pages share 4 hypotheses
Axon Guidance Pathways in Neurodegeneration
mechanism · Pages share 4 hypotheses
Blood-Brain Barrier and Neuroimmune Interface in CBS/PS
mechanism · Pages share 4 hypotheses
COVID-19 Neurodegeneration Mechanism
mechanism · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (3 edges)
therapeutics-section-199-computational-pharmacology-cbs-psp
describes
ent-dise-bfd8f32d
therapeutics-cytoskeletal-dynamics-tubulin-targeting-cbs-psp
describes
ent-dise-bfd8f32d
therapeutics-section-156-pet-therapy-animal-assisted-interventions-cbs-psp
describes
ent-dise-bfd8f32d
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)